127 related articles for article (PubMed ID: 18166919)
1. [Rituximab: mabthera].
Lapeyre H; Joly P
Ann Dermatol Venereol; 2007 Dec; 134(12):968-71. PubMed ID: 18166919
[No Abstract] [Full Text] [Related]
2. Persistent B-cell depletion after rituximab for thrombocytopenic purpura.
Bisogno G
Eur J Pediatr; 2007 Jan; 166(1):85-6. PubMed ID: 16896642
[No Abstract] [Full Text] [Related]
3. Rituximab for patients with idiopathic thrombocytopenic purpura.
Peñalver FJ; Cabrera JR
Ann Intern Med; 2007 Aug; 147(4):281; author reply 281-2. PubMed ID: 17709765
[No Abstract] [Full Text] [Related]
4. Life-threatening infections following rituximab therapy in renal transplant patients with mixed cryoglobulinemia.
Basse G; Ribes D; Kamar N; Esposito L; Rostaing L
Clin Nephrol; 2006 Nov; 66(5):395-6. PubMed ID: 17140171
[No Abstract] [Full Text] [Related]
5. Delayed-onset neutropenia in a patient receiving rituximab as treatment for refractory kidney transplantation.
Mitsuhata N; Fujita R; Ito S; Mannami M; Keimei K
Transplantation; 2005 Nov; 80(9):1355. PubMed ID: 16314808
[No Abstract] [Full Text] [Related]
6. Rituximab: a B-cell depletion therapy for dermatologic disease.
Prajapati V; Mydlarski PR
Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in dermatological diseases.
Troiano M; Lotti T
G Ital Dermatol Venereol; 2009 Aug; 144(4):495-9. PubMed ID: 19755955
[TBL] [Abstract][Full Text] [Related]
8. [Treatment with rituximab of autoimmune disease: results from AADEA's registry].
Callejas Rubio JL; Camps MT; García-Hernández F;
Med Clin (Barc); 2008 Jan; 130(2):79. PubMed ID: 18221681
[No Abstract] [Full Text] [Related]
9. Serum sickness following a first rituximab infusion with no recurrence after the second one.
Mehsen N; Yvon CM; Richez C; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(5):967. PubMed ID: 19032839
[No Abstract] [Full Text] [Related]
10. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report.
Massari M; Catania A; Magnani G
Dig Liver Dis; 2007 Sep; 39 Suppl 1():S134-5. PubMed ID: 17936216
[No Abstract] [Full Text] [Related]
11. [2/2 The other biotherapies].
Fournel C; Medjoub M; Limat S; Woronoff-Lemsi MC
Soins; 2007 Nov; (720):59-61. PubMed ID: 18376755
[No Abstract] [Full Text] [Related]
12. Rituximab in dermatology.
España A; Ornilla E; Panizo C
Actas Dermosifiliogr; 2013 Jun; 104(5):380-92. PubMed ID: 23665436
[TBL] [Abstract][Full Text] [Related]
13. Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement.
Avshovich N; Boulman N; Slobodin G; Zeina AR; Rosner I; Rozenbaum M
Isr Med Assoc J; 2009 Sep; 11(9):566-8. PubMed ID: 19960854
[No Abstract] [Full Text] [Related]
14. Balancing the risks and benefits of rituximab.
Linos E
JAMA Intern Med; 2013 May; 173(10):926. PubMed ID: 23588277
[No Abstract] [Full Text] [Related]
15. [[Treatment of therapy resistant pemphigus vulgaris with rituximab and immunoglobulins].
Mühlhoff C; Megahed M
Hautarzt; 2007 Nov; 58(11):924-6. PubMed ID: 17952393
[No Abstract] [Full Text] [Related]
16. [Biologics in skin diseases other than psoriasis].
Gniadecki R; Skov L
Ugeskr Laeger; 2008 Jun; 170(24):2126-8. PubMed ID: 18565293
[TBL] [Abstract][Full Text] [Related]
17. S3. Rituximab for ANCA-associated vasculitides: the French experience.
Charles P; Guillevin L
Presse Med; 2013 Apr; 42(4 Pt 2):534-6. PubMed ID: 23453207
[No Abstract] [Full Text] [Related]
18. Cerebral toxoplasmosis after rituximab therapy.
Safa G; Darrieux L
JAMA Intern Med; 2013 May; 173(10):924-6. PubMed ID: 23589123
[No Abstract] [Full Text] [Related]
19. Rituximab for severe refractory pediatric Wegener granulomatosis.
Patel AM; Lehman TJ
J Clin Rheumatol; 2008 Oct; 14(5):278-80. PubMed ID: 18824926
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: applications in dermatology.
Fatourechi MM; el-Azhary RA; Gibson LE
Int J Dermatol; 2006 Oct; 45(10):1143-55; quiz 1155. PubMed ID: 17040427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
